Menu
Search Close

Investors

Company Profile

The information on this web site is being disclosed for the purposes of AIM Rule 26 and was last updated on 20 February 2019.

The main country of operation and country of incorporation is the UK. Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market and is developing a pipeline of immunotherapies for the treatment of cancer based on its patented ImmunoBody® and Moditope® platforms. The Company's mission is to develop therapeutic cancer vaccines that stimulate the patient's immune system to mount an active response to 'reject' or kill the growing tumour.

Webcasts, Interviews and Media Coverage

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

Tue, 12 Feb 2019 15:07:00

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".

Thu, 31 Jan 2019 08:41:00

Award shortlist 'a significant scientific endorsement' of Scancell's technology

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive London's Andrew Scott the company's received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for a major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

Wed, 23 Jan 2019 12:25:00